摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-4,5-二氟苯甲酸甲酯 | 207346-42-7

中文名称
2-氨基-4,5-二氟苯甲酸甲酯
中文别名
4,5-二氟-2-氨基苯甲酸甲酯;甲基2-氨基-4,5-二氟苯;2-氨基-4.5-二氟苯甲酸甲酯
英文名称
methyl 2-amino-4,5-difluorobenzoate
英文别名
methyl 4,5-difluoroanthranilate;2-amino-4,5-difluoro-benzoic acid,methyl ester
2-氨基-4,5-二氟苯甲酸甲酯化学式
CAS
207346-42-7
化学式
C8H7F2NO2
mdl
MFCD09264511
分子量
187.146
InChiKey
VIAQNTRKUPBQKR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    274.1±40.0 °C(Predicted)
  • 密度:
    1.355±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2922499990
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温。

SDS

SDS:9882ffb44f128909fc771694a272c177
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 2-amino-4,5-difluorobenzoate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-amino-4,5-difluorobenzoate
CAS number: 207346-42-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7F2NO2
Molecular weight: 187.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

2-氨基-4,5-二氟苯甲酸甲酯是一种医药中间体,可用于制备依诺格雷。

制备

2-氨基-4,5-二氟苯甲酸甲酯可通过四步反应从3,4-二氟苯胺为原料制备得到。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma
    作者:Xuewu Liang、Chenxia Sun、Chunpu Li、Haolan Yu、Xiaohui Wei、Xuyi Liu、Wei Bao、Yuqiang Shi、Xiaochen Sun、Mirzadavlat Khamrakulov、Chenghua Yang、Hong Liu
    DOI:10.1021/acs.jmedchem.1c00466
    日期:2021.7.8
    lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors is of great value and significance in the treatment of neoplastic disorders and inflammatory and autoimmune diseases. However, there is a lack of effective MALT1 inhibitors in clinic. Herein, a novel class of potent 5-oxo-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-based MALT1 inhibitors and their covalent derivatives were first identified
    黏膜相关淋巴组织淋巴瘤易位蛋白 1 (MALT1) 抑制剂的开发在肿瘤性疾病、炎症和自身免疫性疾病的治疗中具有重要价值和意义。然而,临床上缺乏有效的MALT1抑制剂。在此,首次通过高通量鉴定和设计了一类新型有效的 5-oxo-1-thioxo-4,5-dihydro-1 H - thiazolo[3,4- a ]quinazoline 抑制剂及其共价衍生物。筛选。我们证明了化合物15c、15e和20c有效抑制 MALT1 蛋白酶并对活化的 B 细胞样弥漫性大 B 细胞淋巴瘤具有低个位数微摩尔效力显示出选择性细胞毒性。此外,化合物20c以剂量依赖性方式特异性抑制 MALT1 依赖性 TMD8 细胞中的 NF-κB 信号传导并诱导细胞凋亡。更重要的是,20c在 TMD8 异种移植肿瘤模型中显示出良好的药代动力学特性和抗肿瘤功效,且无显着毒性。总的来说,这项研究为 MALT1 抑制剂的进一步结构
  • Reductive Ring Closure Methodology toward Heteroacenes Bearing a Dihydropyrrolo[3,2-<i>b</i>]pyrrole Core: Scope and Limitation
    作者:Li Qiu、Xiao Wang、Na Zhao、Shiliang Xu、Zengjian An、Xuhui Zhuang、Zhenggang Lan、Lirong Wen、Xiaobo Wan
    DOI:10.1021/jo501402n
    日期:2014.12.5
    reductive ring closure methodology to heteroacenes bearing a dihydropyrrolo[3,2-b]pyrrole core was systematically studied for its scope and limitation. The methodology involves (i) the cyclization of an o-aminobenzoic acid ester derivative to give an eight-membered cyclic dilactam, and (ii) the conversion of the dilactams into the corresponding diimidoyl chloride, which undergoes (iii) reductive ring closure
    针对其具有范围和局限性,系统地研究了一种新开发的带有二氢吡咯并[3,2- b ]吡咯核的杂环丁烷的还原性闭环方法。该方法涉及(i)邻氨基苯甲酸酯衍生物的环化以产生八元环状双内酰胺,和(ii)将双内酰胺转化成相应的二亚氨基酰氯,其经历(iii)还原性闭环以安装二氢吡咯并[3,2- b]吡咯核。该方法的第一步由于其底物限制而起关键作用,该底物受到低聚和水解竞争的困扰。所有的双内酰胺都可以成功地转化为相应的二亚氨基氯化物,其中大多数成功地得到了二氢吡咯并[3,2- b]吡咯核。然后使用紫外-可见光谱和循环伏安法系统地研究了取代基和共轭长度的延长对所得杂苯的光物理性质的影响。发现氯化和氟化对杂并苯的光物理性质有很大不同的影响,并且环熔合样式也对杂并苯的带隙有很大的影响。成功地制备一系列带有二氢吡咯并[3,2- b ]吡咯核的杂并苯将为进一步制造有机场效应晶体管器件提供各种各样的候选物。
  • TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
    申请人:Gilead Sciences, Inc.
    公开号:US20160289229A1
    公开(公告)日:2016-10-06
    The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
    本公开涉及调节类似受体调节剂化合物,例如二氨基吡啶并[3,2 D]嘧啶化合物和药物组合物,其中调节类似受体(例如TLR-8),以及制备和使用它们的方法。
  • NITROGEN CONTAINING HETEROARYL COMPOUNDS
    申请人:Bleicher Konrad
    公开号:US20110306589A1
    公开(公告)日:2011-12-15
    The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
    这项发明涉及一种新颖的含氮杂环芳基化合物,其化学式为(I),其中A1、A2、R1、R2、R3、R4、R5和R6如描述和索赔中所定义,并且其生理上可接受的盐和酯。这些化合物抑制PDE10A并可用作治疗药物。
  • [EN] ERBB/BTK INHIBITORS<br/>[FR] INHIBITEURS DE ERBB/BTK
    申请人:DIZAL JIANGSU PHARMACEUTICAL CO LTD
    公开号:WO2019149164A1
    公开(公告)日:2019-08-08
    Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    揭示了抑制ErbBs(例如EGFR或Her 2),特别是ErbBs的突变形式,以及BTK的化合物,其药用盐、水合物、溶剂合物或立体异构体,以及包含这些化合物的药物组合物。该化合物和药物组合物可以有效治疗ErbBs(特别是ErbBs的突变形式)或与BTK相关的疾病,包括癌症。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐